Articles

'Instituting' some changes

New MD Anderson institute to bridge academia, industry 'valley of death'
Written byKelsey Kaustinen
| 4 min read

HOUSTON--Never one to let any moss grow underneath it, The University of Texas MD Anderson Cancer Center recently announced the establishment of a new specialized research institute. The Institute for Applied Cancer Science will seek to "identify and validate new cancer targets, convert the scientific knowledge into new cancer drugs and advance the novel agents into innovative clinical trials through a streamlined collaboration between academic medicine and the biotechnology industry."

The institute will focus on the development of a pipeline through multidisciplinary collaboration of several programs at MD Anderson, bringing together researchers from academia and industry. The disconnect between the different foci of academia and industry is something the leaders of the new institute refer to as the "valley of death" in the drug development process.

"Efficient conversion of discoveries into effective medicines will require seamless integration of not only discovery and applied science, but also the exploratory and goal-oriented cultures in academia and industry," Raymond DuBois, M.D., Ph.D., executive vice president and provost at MD Anderson, said in a press release. "Our institute leaders are highly accomplished in both realms and have outstanding experience in bridging the gap between them."

To continue reading this article, subscribe for FREE toDrug Discovery News Logo

Subscribe today to keep up to date with the latest advancements and discoveries in drug development achieved by scientists in pharma, biotech, non-profit, academic, clinical, and government labs.

Add Drug Discovery News as a preferred source on Google

Add Drug Discovery News as a preferred Google source to see more of our trusted coverage.

About the Author

Here are some related topics that may interest you:

Subscribe to Newsletter

Subscribe to our eNewsletters

Stay connected with all of the latest from Drug Discovery News.

Subscribe

Sponsored

Gloved hand holding a multiwell cell culture plate under a fluorescence microscope for spheroid analysis.
Using confocal live-cell imaging to characterize immune-mediated cytotoxicity over time.
Fluorescence microscopy image of cells displaying green and red fluorescent signals.
Using confocal live-cell imaging to assess treatment effects in spheroids, organoids, and co-cultures.
3D illustration of Y-shaped antibody molecules floating against a soft blue background, with a detailed antibody structure in the foreground.
From molecular developability to functional activity, integrated characterization strategies help inform lead selection and optimization in biologics discovery.